A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Subjects With Hematologic Malignancies

Trial Profile

A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Subjects With Hematologic Malignancies

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Dec 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Nivolumab (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 20 Dec 2017 Planned primary completion date changed from 28 Nov 2017 to 15 Jul 2019.
    • 20 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Dec 2017 Results (as of 8 Jun 2017) assessing safety and efficacy of Ibrutinib and Nivolumab, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top